(410 ILCS 416/25)
    Sec. 25. Reimbursement requirements; notice.
    (a) A reimbursement under the program at a trial site that conducts clinical trials must:
        (1) be reviewed and approved by the institutional review board associated with the
    
clinical trial for which the reimbursement is provided; and
        (2) comply with applicable federal and State laws.
    (b) The independent third-party organization operating the program is not required to obtain approval from an institutional review board with respect to the financial eligibility of a subject who is medically eligible for a clinical trial.
    (c) The independent third-party organization operating the program shall provide written notice to a subject on:
        (1) the nature, availability, and scope of the ancillary financial support under the
    
program; and
        (2) the program's general guidelines on financial eligibility.
(Source: P.A. 103-227, eff. 6-30-23.)